Literature DB >> 27798458

The angiotensin type 2 receptor and the kidney.

Antonio A B Peluso1, Robson A S Santos, Thomas Unger, U Muscha Steckelings.   

Abstract

PURPOSE OF REVIEW: Angiotensin II is a main regulator of kidney function. Renal actions mediated by the angiotensin AT1 receptor have been well known for many years. In contrast, several details of angiotensin AT2 receptor actions in kidney physiology and pathophysiology were only described very recently. These findings are reviewed in this article. RECENT
FINDINGS: Regarding the role of the angiotensin AT2 receptor in kidney physiology, a major recent finding was that the AT2 receptor-mediated inhibition of Na-H exchanger-3 and Na/K-ATPase in the renal proximal tubules is caused by internalisation of these transporters, thus reducing reabsorption and increasing natriuresis/diuresis. Regarding renal pathology, several studies demonstrated an attenuation of renal injury caused by diabetes or by obesity with or without high-salt diet through anti-inflammatory, antifibrotic, and antioxidative mechanisms. Generally, AT2 receptor expression seems increased and AT2 receptor-mediated effects stronger in female and obese animals.
SUMMARY: The recent findings about the role of the angiotensin AT2 receptor in renal health and disease strongly suggest that pharmacological targeting of this receptor with selective agonists is a promising therapeutic strategy for inducing diuresis/natriuresis (also additive to established diuretics) and for the treatment of diabetic nephropathy or kidney disease of other pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27798458     DOI: 10.1097/MNH.0000000000000289

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  7 in total

Review 1.  Long-term neprilysin inhibition - implications for ARNIs.

Authors:  Duncan J Campbell
Journal:  Nat Rev Cardiol       Date:  2016-12-15       Impact factor: 32.419

2.  Benchmarking renin suppression and blood pressure reduction of direct renin inhibitor imarikiren through quantitative systems pharmacology modeling.

Authors:  Yeshitila Gebremichael; Gezim Lahu; Majid Vakilynejad; K Melissa Hallow
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-11-16       Impact factor: 2.745

3.  Identification of a Primary Renal AT2 Receptor Defect in Spontaneously Hypertensive Rats.

Authors:  Brandon A Kemp; Nancy L Howell; John J Gildea; Susanna R Keller; Robert M Carey
Journal:  Circ Res       Date:  2020-01-30       Impact factor: 17.367

4.  AT1R-AT2R-RXFP1 Functional Crosstalk in Myofibroblasts: Impact on the Therapeutic Targeting of Renal and Cardiac Fibrosis.

Authors:  Bryna S M Chow; Martina Kocan; Matthew Shen; Yan Wang; Lei Han; Jacqueline Y Chew; Chao Wang; Sanja Bosnyak; Katrina M Mirabito-Colafella; Giannie Barsha; Belinda Wigg; Elizabeth K M Johnstone; Mohammed A Hossain; Kevin D G Pfleger; Kate M Denton; Robert E Widdop; Roger J Summers; Ross A D Bathgate; Tim D Hewitson; Chrishan S Samuel
Journal:  J Am Soc Nephrol       Date:  2019-09-11       Impact factor: 10.121

5.  Defective Renal Angiotensin III and AT2 Receptor Signaling in Prehypertensive Spontaneously Hypertensive Rats.

Authors:  Brandon A Kemp; Nancy L Howell; Susanna R Keller; John J Gildea; Weijian Shao; Luis Gabriel Navar; Robert M Carey
Journal:  J Am Heart Assoc       Date:  2019-05-07       Impact factor: 5.501

Review 6.  The relaxin family peptide receptor 1 (RXFP1): An emerging player in human health and disease.

Authors:  Ting-Yun Chen; Xiaoyun Li; Ching-Hsia Hung; Harinath Bahudhanapati; Jiangning Tan; Daniel J Kass; Yingze Zhang
Journal:  Mol Genet Genomic Med       Date:  2020-02-26       Impact factor: 2.183

Review 7.  Angiotensin and Endothelin Receptor Structures With Implications for Signaling Regulation and Pharmacological Targeting.

Authors:  David Speck; Gunnar Kleinau; Michal Szczepek; Dennis Kwiatkowski; Rusan Catar; Aurélie Philippe; Patrick Scheerer
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-19       Impact factor: 6.055

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.